$FBDS
Fuss Brands Corp.

2024 Q1 Form 10-K Financial Statement

#000182912624000716 Filed on February 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $45.01K $141.3K $178.5K
YoY Change -34.13% 275.76% 1785.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $45.01K $141.3K $178.5K
YoY Change -34.13% 275.76% 1785.24%
Operating Profit -$45.01K -$178.5K
YoY Change -34.13%
Interest Expense $1.250K -$1.260K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$46.26K -$142.5K -$178.5K
YoY Change -32.3% 279.12% 1785.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$46.26K -$142.5K -$178.5K
YoY Change -32.3% 279.12% 1785.24%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 19.09M shares 15.45M shares
Diluted Shares Outstanding 19.09M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.440K $9.450K $11.41K
YoY Change -63.71% -73.41%
Cash & Equivalents $5.444K $9.448K $11.41K
Short-Term Investments
Other Short-Term Assets $158.4K $129.9K $6.660K
YoY Change 5178.33%
Inventory
Prepaid Expenses $158.3K $129.9K $6.660K
Receivables
Other Receivables
Total Short-Term Assets $163.8K $139.4K $18.07K
YoY Change 810.45% 292.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $1.00 -$6.00 $1.00
YoY Change -66.67%
TOTAL ASSETS
Total Short-Term Assets $163.8K $139.4K $18.07K
Total Long-Term Assets $1.00 -$6.00 $1.00
Total Assets $163.8K $139.4K $18.07K
YoY Change 810.3% 292.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.43K $106.0K $39.99K
YoY Change -6.6% 10042.68%
Accrued Expenses $158.2K $157.0K $70.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $247.4K $98.38K $98.38K
YoY Change 151.45% 0.0% 20.56%
Long-Term Debt Due $50.00K $50.00K
YoY Change
Total Short-Term Liabilities $658.7K $588.0K $208.4K
YoY Change 419.96% 491.4% 155.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $658.7K $588.0K $208.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $658.7K $588.0K $208.4K
YoY Change 419.96% 491.4% 155.36%
SHAREHOLDERS EQUITY
Retained Earnings -$12.73M -$12.68M -$12.42M
YoY Change 3.95% 4.15%
Common Stock $19.09K $19.09K $15.45K
YoY Change 24.98% 28.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$494.9K -$448.6K -$190.3K
YoY Change
Total Liabilities & Shareholders Equity $163.8K $139.4K $18.07K
YoY Change 810.3% 292.14%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q2
OPERATING ACTIVITIES
Net Income -$46.26K -$142.5K -$178.5K
YoY Change -32.3% 279.12% 1785.24%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$153.0K -$13.59K -$3.580K
YoY Change 247.16% -65.74% -62.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $149.0K 0.000 -10.00
YoY Change 533.34% -100.0% -100.11%
NET CHANGE
Cash From Operating Activities -$153.0K -13.59K -3.580K
Cash From Investing Activities 0.000
Cash From Financing Activities $149.0K 0.000 -10.00
Net Change In Cash -$4.004K -13.59K -3.590K
YoY Change -80.51% -11.18%
FREE CASH FLOW
Cash From Operating Activities -$153.0K -$13.59K -$3.580K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 us-gaap Revenues
Revenues
usd
CY2022 us-gaap Revenues
Revenues
usd
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000926844
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 us-gaap Interest Expense
InterestExpense
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 fbds Conversion Of Series Preferred To Common Stock
ConversionOfSeriesPreferredToCommonStock
usd
CY2022 fbds Misc Adjustment To Reflect Rounding On Reverse Split
MiscAdjustmentToReflectRoundingOnReverseSplit
usd
CY2023 fbds Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-10-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-34808
CY2023 dei Entity Registrant Name
EntityRegistrantName
FUSS BRANDS CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-3143424
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
80 Broad Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10004
CY2023 dei City Area Code
CityAreaCode
917
CY2023 dei Local Phone Number
LocalPhoneNumber
720-3366
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
7354325 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19090078 shares
CY2023 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2023 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2023Q4 us-gaap Cash
Cash
9448 usd
CY2022Q4 us-gaap Cash
Cash
35539 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
129917 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
-0 usd
CY2023Q4 us-gaap Assets
Assets
139364 usd
CY2022Q4 us-gaap Assets
Assets
35539 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
105991 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1045 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156978 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
-0 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
50000 usd
CY2023Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2022Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
588007 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99426 usd
CY2023Q4 us-gaap Liabilities
Liabilities
588007 usd
CY2022Q4 us-gaap Liabilities
Liabilities
99426 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
834 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
838 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14883665 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14883665 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19090 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14884 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12287167 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12170928 usd
CY2023Q4 fbds Discount On Common Stocks
DiscountOnCommonStocks
-75889 usd
CY2022Q4 fbds Discount On Common Stocks
DiscountOnCommonStocks
-75889 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12679846 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12174648 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-448643 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63887 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139364 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35539 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
503078 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
107411 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
503078 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
107411 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-503078 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-107411 usd
CY2023 us-gaap Interest Expense
InterestExpense
2119 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-505197 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107411 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-505197 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-107411 usd
CY2023 fbds Basic And Diluted Earningsloss Per Common Share
BasicAndDilutedEarningslossPerCommonShare
-0.03
CY2022 fbds Basic And Diluted Earningsloss Per Common Share
BasicAndDilutedEarningslossPerCommonShare
-0.01
CY2023 fbds Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
16356328 shares
CY2022 fbds Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
7666944 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-31438 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-107411 usd
CY2022 fbds Private Placement Of Common Shares
PrivatePlacementOfCommonShares
74962 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63887 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63887 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-505197 usd
CY2023 fbds Private Placement Of Common Stock
PrivatePlacementOfCommonStock
23525 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
96916 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-448643 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
505197 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
107411 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
96916 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
129917 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
104946 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1045 usd
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
176658 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
156978 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99615 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106366 usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23525 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
74962 usd
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
50000 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
66943 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73525 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141905 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26091 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
35539 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35539 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9448 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35539 usd
CY2023Q1 fbds Purchase Amount
PurchaseAmount
925000 usd
CY2023Q4 fbds Negative Working Capital
NegativeWorkingCapital
448643 usd
CY2023Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
-448643 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zZHt07YC1Enl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zBmHKOOififj">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amount of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 26
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
450060 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
273402 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
176658 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
129917 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9448 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35539 usd
CY2021 fbds Related Party Expenses
RelatedPartyExpenses
43650 usd
CY2023 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
43650 usd
CY2023Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2022Q4 fbds Notes Payable Related Party
NotesPayableRelatedParty
98381 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 26
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50593 usd
CY2022Q3 fbds Discount On Common Stock
DiscountOnCommonStock
-75889 usd
fbds Conversion Of Prefered Shareholders Into Common Stock Shares
ConversionOfPreferedShareholdersIntoCommonStockShares
3645 shares
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
3645000 shares
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1000 to 1
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19090078 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19090078 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14883665 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14883665 shares
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23525 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
96917 usd
CY2022Q2 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1,000 to 1 ratio
CY2022Q2 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
6234654 shares
CY2021Q2 fbds Preferred Stock Shares Designated
PreferredStockSharesDesignated
2500000 shares
CY2021 fbds Stock Based Compensation Related Party
StockBasedCompensationRelatedParty
250000 usd
CY2023 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
one thousand (1,000) fully paid and nonassessable shares of Common Stock (the “Series A-1 Conversion Ratio”).
CY2022Q2 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1,000 to 1 ratio
CY2023Q4 us-gaap Other Commitment
OtherCommitment
0 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
0 usd

Files In Submission

Name View Source Status
0001829126-24-000716-index-headers.html Edgar Link pending
0001829126-24-000716-index.html Edgar Link pending
0001829126-24-000716.txt Edgar Link pending
0001829126-24-000716-xbrl.zip Edgar Link pending
fbds-20231031.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fussbrands_10k.htm Edgar Link pending
fussbrands_ex31-1.htm Edgar Link pending
fussbrands_ex32-1.htm Edgar Link pending
fbds-20231031_cal.xml Edgar Link unprocessable
fbds-20231031_def.xml Edgar Link unprocessable
fbds-20231031_lab.xml Edgar Link unprocessable
fbds-20231031_pre.xml Edgar Link unprocessable
fussbrands_10k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable